The ability of SMARCA2 to compensate for the loss of SMARCA4 has made SMARCA2 an attractive therapeutic target for SMARCA4-mutant tumor types, motivating multiple groups to generate SMARCA2 small molecule inhibitors or degraders26–28. This evidence concerns the gene SMARCA4 and neoplasm.